Prospects Fund

Prospects Oncology Fund

prospect-oncology-fund-imgFACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Ontario First Investment Strategy and have the potential to act as deal flow for the Compass Rose Fund. Prospects funding ranges between $50,000 and $200,000.

Funding is governed by a research contract which grants certain rights to FACIT.   FACIT receives no financial consideration on Prospects awards of $50,000 or less (***new limit as of September 2019***).  On all other awards, FACIT receives an option to make an investment at the Compass Rose level and act as the agent for commercialization, if mutually agreed.  If the option is exercised, funding received from the Prospects Fund will be credited towards FACIT's Compass Rose investment.

How to apply:

The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:

  • March 31
  • September 30

The pre-submission form can be downloaded here.

Late applications will not be considered.

Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.

Select Prospects Funded Projects

Prospects Fund (Other)

At-home prostate cancer screening kit

A semen-based screening test for prostate cancer that allows easy and fast specimen collection at home.

At-home prostate cancer screening kitAt-home prostate cancer screening kit


Hand-held device for detecting tumour margins during lumpectomies

Multi-Magnetics is developing a hand-held device that uses photoacoustic imaging to detect tumour margins and residual disease in the surgical cavity during breast-conserving (lumpectomy) surgery.

Hand-held device for detecting tumour margins during lumpectomiesHand-held device for detecting tumour margins during lumpectomies


Small-molecule inhibitors that target cancer cell mitochondria

Development of novel small-molecule inhibitors that target cancer cell mitochondria, a fuel source that many cancer cells rely on during chemotherapy.

Small-molecule inhibitors that target cancer cell mitochondriaSmall-molecule inhibitors that target cancer cell mitochondria


Scaling clinical expertise with AI to automate and improve the delivery of cancer care

Bridge7 uses AI to automate & improve the efficiency, consistency & quality of delivering cancer care.

Scaling clinical expertise with AI to automate and improve the delivery of cancer careScaling clinical expertise with AI to automate and improve the delivery of cancer care


View All Prospects Funded Projects